Enhancing the efficacy of glycolytic blockade in cancer cells via RAD51 inhibition

Targeting the early steps of the glycolysis pathway in cancers is a well-established therapeutic strategy; however, the doses required to elicit a therapeutic effect on the cancer can be toxic to the patient. Consequently, numerous preclinical and clinical studies have combined glycolytic blockade w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, John J., Chow, Kin-hoe, Labrie, Nathan J., Branca, Jane A., Sproule, Thomas J., Perkins, Bryant R. A., Wolf, Elise E., Costa, Mauro, Stafford, Grace, Rosales, Christine, Mills, Kevin D., Roopenian, Derry C., Hasham, Muneer G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343731/
https://www.ncbi.nlm.nih.gov/pubmed/30183475
http://dx.doi.org/10.1080/15384047.2018.1507666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343731/
https://www.ncbi.nlm.nih.gov/pubmed/30183475
http://dx.doi.org/10.1080/15384047.2018.1507666

Ejemplares similares